Personalis Inc(PSNL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:01 PM ET (Korea 10/28 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.09 | Insider Own | 32.64% | Shs Outstand | 106.4M | Perf Week | 0.25% |
| Market Cap | 1.73B | Forward P/E | - | EPS next Y | 9.45% | Insider Trans | -1.53% | Shs Float | 73.0M | Perf Month | -2.08% |
| Enterprise Value | 1.56B | PEG | - | EPS next Q | -0.26 | Inst Own | 59.35% | Short Float | 9.3% | Perf Quarter | 36.23% |
| Income | -0.11B | P/S | 24.86 | EPS this Y | -20.15% | Inst Trans | 3.15% | Short Ratio | 2.41 | Perf Half Y | 190.55% |
| Sales | 0.07B | P/B | 7.23 | EPS next 5Y | 6.66% | ROA | -37.55% | Short Interest | 6.79M | Perf YTD | 100.75% |
| Book/sh | 2.21 | P/C | 8.14 | EPS past 3/5Y | 28.38% 2.91% | ROE | -50.32% | 52W High | -15.4% ($18.89) | Perf Year | 65.08% |
| Cash/sh | 1.96 | P/FCF | - | Sales past 3/5Y | 2.3% -2.4% | ROIC | -40.39% | 52W Low | 222.5% ($4.95) | Perf 3Y | 1547.25% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 14.26% | Gross Margin | 12.69% | Volatility(W/M) | 1.86% 2.09% | Perf 5Y | -13.9% |
| Dividend TTM | - | EV/Sales | 22.35 | Sales Y/Y TTM | -13.26% | Oper. Margin | -164.07% | ATR (14) | 0.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.08 | EPS Q/Q | -32.61% | Profit Margin | -153.84% | RSI (14) | 50.09 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.24 | Sales Q/Q | 29.96% | SMA20 | 0% ($15.98) | Beta | 2.41 | Target Price | $16.25 |
| Payout | - | Debt/Eq | 0.16 | Earnings | 2026/8/4 | SMA50 | -2.05% ($16.31) | Rel Volume | 0.65 | Prev Close | $15.88 |
| Employees | 260 | LT Debt/Eq | 0.13 | EPS/Sales Surpr. | -13.94% 33.97% | SMA200 | 42.92% ($11.18) | Avg Volume(3M) | 2.82M | Price | $15.98 |
| IPO | 2019/6/20 | Option/Short | Yes/Yes | Trades | 8142 | Volume | 1,829,270 | Change | 0.63% |
🧬 Personalis (PSNL) is a US diagnostics and research company specializing in advanced genomic analysis for precision oncology. With a core focus on monitoring minimal residual disease (MRD) in cancer patients and tumor genomic profiling, the company provides clinical diagnostic services that leverage ultra-sensitive testing technology to support cancer recurrence surveillance and treatment response assessment.
Over the past 1 year, on the higher side
15% below its 1-year high.
Traded less than usual. That is 65% of its average volume.
PSNL has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -20.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,486. Peers typically go for $451.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -13.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 59.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #27 of 44 in the industry
Based on market cap of $2B.
NEO#25 Neogenomics Inc $2B PER - 
WGS#26 GeneDx Holdings Corp $2B PER - PSNL#27 Personalis Inc $2B PER - 
FRNM#28 Freenome Inc $1B PER - 
OPK#29 Opko Health Inc $1B PER - 
FAQ
What kind of company is PSNL?
PSNL belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of PSNL?
The market cap of PSNL is approximately $1.7B, ranking 2,175 within its sector.
What is the 52-week high and low for PSNL?
PSNL has recorded a 52-week high of $18.89 and a low of $4.95.
